CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 28 enrolled
Drug / intervention
NKTR-214drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02869295
NCT02869295Phase 2Completed
CompareCT.gov

An Open-Label, Multicenter, Dose Escalation And Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumor Malignancies

Nektar Therapeutics·interventional·Posted Aug 16, 2016·Updated Jul 29, 2021

In Brief

A Phase 2 clinical trial evaluating NKTR-214 for Unspecified Adult Solid Tumor, Protocol Specific. Completed, enrolled 28 participants across 3 sites.

Detailed Summary

This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study of NKTR-214 in adult patients with locally advanced or metastatic solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUnspecified Adult Solid Tumor, Protocol Specific
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 16, 2016
Enrollment StartDec 1, 2015
Primary CompletionOct 31, 2018
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 9.9 years ago

Interventions

NKTR-214drug

Participants in the dose escalation cohorts will be treated every 21 days (q21d) or every 14 days (q14d) until tumor progression.